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Background: Inﬂuenza-related pneumonia, referred to as inﬂuenza pneumonia, was
reported relatively more frequently during a recent inﬂuenza pandemic in 2009. The
validity of adapting routine pneumonia severity prediction models for various types of
pneumonia is unclear.
Methods: We conducted a nationwide survey to evaluate inﬂuenza pneumonia among adult
patients in Japan. Questionnaires were sent to physicians working in departments of
respiratory medicine at 2491 hospitals. Both the outcome and pneumonia severity, using
invasive positive pressure ventilation (IPPV) as an indicator, were evaluated by routine
pneumonia severity index (PSI), CURB-65 (confusion, urea, respiratory rate, blood pressure,
and ageZ65 years), and A-DROP (age, dehydration, respiration, disorientation, and blood
pressure).
Results: Data collected from 320 patients with inﬂuenza pneumonia, including 25 cases (7.8%)
of death and 43 (13.4%) of IPPV, were analyzed. Although all routine prediction models showed
that higher mortality tended to be associated with a higher risk class/grade, the actual
mortality rates were higher than predicted. The risk class of mortality calculated by the PSI was
inﬂuenced by pneumonia patterns. Although pneumonia severity was similarly predicted, the
types of pneumonia also affected severity in all prediction models. A-DROP showed the highest
accuracy on receiver operating characteristic analysis for both mortality and severity.
Conclusions: CURB-65 and A-DROP are fair predictors of mortality regardless of pneumonia
patterns. However, the current pneumonia prediction models may underestimate the severity
and appropriate site of care for patients with inﬂuenza pneumonia.
& 2014 The Japanese Respiratory Society. Published by Elsevier B.V. Open access under 
CC BY-NC-ND license.Society. Published by Elsevier B.V. Open access under CC BY-NC-ND license.
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Inﬂuenza has a worldwide distribution and causes increased
morbidity and mortality each year [1]. Pneumonia develops in
some patients with inﬂuenza, which can lead to inﬂuenza-
related death. Inﬂuenza-related pneumonia, referred to as
inﬂuenza pneumonia, was reported relatively more fre-
quently in the inﬂuenza pandemic of 2009, with signiﬁcant
morbidity and mortality worldwide [2–6].
Severity evaluation and prediction models have been
established to manage patients with pneumonia, make clin-
ical decisions, and improve outcome, especially in cases of
community-acquired pneumonia (CAP). The major guidelines
for CAP evaluation and prediction models include the pneu-
monia severity index (PSI) from the Infectious Diseases
Society of America [7] and CURB-65 (confusion, urea, respira-
tory rate, blood pressure, and age Z65 years) from the British
Thoracic Society [8]. In Japan, the A-DROP (age, dehydration,
respiration, disorientation, and blood pressure) scoring sys-
tem from the Japanese Respiratory Society [9] is usually
adapted for patients with CAP. These models are validated
and recommended as clinical guidelines [10]. On the other
hand, some reports on the recent inﬂuenza pandemic sug-
gested that routine prediction models such as the PSI and
CURB-65 failed to predict the need for mechanical ventilation
or to estimate mortality [11–13].
In the 2009 inﬂuenza pandemic, some patients with severe
inﬂuenza pneumonia presented with viral pneumonia with
poor outcome, which is not typical of the usual form of CAP.
Three manifestations of pneumonia associated with inﬂu-
enza are well described [14]; therefore, the validity of adapt-
ing routine prediction for various types of pneumonia is
unclear.
In a previous study, we collected and analyzed data from
346 cases of inﬂuenza pneumonia, including 27 fatal cases
[15]. The present study uses the same dataset to evaluate
each routine pneumonia prediction model and the effects of
inﬂuenza pneumonia among adult patients in Japan.2. Materials and methods
2.1. Study design and data collection
In a retrospective cohort study of adult patients with inﬂu-
enza pneumonia, questionnaires were sent to physicians
working in departments of respiratory medicine at 2491
hospitals (4200 beds) across Japan. Data were collected by
mail. This study conformed to the principles of the Declara-
tion of Helsinki and was approved by the Institutional Review
Board (Approval no. 778, 26/4/2010).Abbreviations: CAP, community-acquired pneumonia; IPPV, invas
ROC, receiver operating characteristic
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The inﬂuenza pandemic period was deﬁned as April 1, 2009–
April 30, 2010. Patients were given a diagnosis of pandemic
inﬂuenza (H1N1) 2009 by rapid immunoﬂuorescence inﬂu-
enza diagnostic kits or reverse transcription polymerase
chain reaction. From the epidemiological data, it is generally
accepted that rapid diagnostic kit results showing inﬂuenza A
infection indicated H1N1 infection during this pandemic
period [16].
Pneumonia was diagnosed by an attending physician
based on respiratory symptoms and the ﬁndings of physical
and radiological examinations. Inﬂuenza pneumonia is clas-
siﬁed into three categories according to the deﬁnition by
Louria et al. [14]: (1) pure inﬂuenza viral pneumonia (i.e.,
primary inﬂuenza pneumonia where pneumonia is caused
only by the inﬂuenza virus and no bacterial pathogens are
detected), (2) secondary bacterial pneumonia (i.e., inﬂuenza is
complicated by secondary bacterial pneumonia that develops
once the inﬂuenza symptoms have resolved), and (3) mixed
viral and bacterial pneumonia (i.e., the inﬂuenza virus and
bacterial pneumonia occur concurrently).
2.3. Questionnaires
Age (in 10-year brackets), sex, and comorbid conditions were
recorded. As described in the study deﬁnition, all pneumonia
cases were classiﬁed as pure inﬂuenza viral pneumonia,
secondary bacterial pneumonia, mixed viral and bacterial
pneumonia, or miscellaneous according to the attending
physician's diagnosis. Invasive positive pressure ventilation
(IPPV) use, treatment options, and outcome data were also
collected.
2.4. Pneumonia severity evaluation
The severity of inﬂuenza pneumonia was estimated using
routine PSI, CURB-65, and A-DROP. In all cases, age was
expressed as the median of each class.
Patients were categorized into ﬁve classes by the PSI
score [7] and into the following three groups according to
the CURB-65 score: “group 1: mortality low” with a score of 0
or 1; “group 2: mortality intermediate” with a score of 2; and
“group 3: mortality high” with a score of Z3 [8].
The A-DROP system is based on the following ﬁve clinical
features: age (A), dehydration (D), respiration (R), orientation (O),
and blood pressure (P). According to this system, cases are
classiﬁed as “mild” when none of the ﬁve criteria are met,
“moderate” when one or two of the criteria are met, “severe”
when three of the criteria are met, or “extremely severe” when
four or ﬁve of the criteria are met. Cases of shock or altered
mental status are regarded as extremely severe [9].ive positive pressure ventilation; PSI, pneumonia severity index;
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The primary measures were used to evaluate validity in
terms of mortality by the routine prediction models (PSI,
CURB-65, and A-DROP) for inﬂuenza pneumonia and the
inﬂuence of pneumonia patterns. Secondary measures were
used to evaluate pneumonia severity by using IPPV as an
indicator [17]. The effect of pneumonia patterns on mortality
or severity was also analyzed.
Frequency analysis, with results expressed as percentages,
was used for the descriptive statistics of nonparametric data.
We performed the Shapiro–Wilk test for normality and
the Kruskal–Wallis test for age-group comparisons. The
Chi-square test was used to analyze pneumonia severity,
use of mechanical ventilation, and outcomes, and the Fisher
exact test was used to analyze small samples. The Cochran–
Armitage test was used for trend analysis, and multiple
logistic regression models were performed to analyze risk
estimation. Po0.05 was considered signiﬁcant. All statistical
analyses were performed using SPSS version 21.0.0.2 (IBM
Corporation, Armonk, NY) and R version 2.15.3 (R Foundation
for Statistical Computing, Vienna, Austria) software.3. Results
3.1. Patients
We collected data on 346 cases of inﬂuenza pneumonia from
994 physicians (overall questionnaire response rate, 39.9%).
Patient characteristics, comorbid conditions, treatments, and
outcomes are described elsewhere. We excluded 26 cases
from the analysis because of insufﬁcient data to enable a
severity calculation (Fig. 1).
3.2. Patient background, symptoms, and ﬁndings
Of the remaining 320 cases, pure inﬂuenza viral pneumonia
was accounted for in 94 patients (29.4%), mixed viral and
bacterial pneumonia in 127 (39.7%), secondary bacterial pneu-
monia in 53 (16.6%), and miscellaneous in 46 (14.4%). In
addition, the dataset included 43 cases of IPPV (13.4%) and 25
cases of death (7.8%). The in-hospital mortality rate was 8.6%.
Patient background, symptoms, and ﬁndings for each
group (excluding the miscellaneous group) are given inFig. 1 – Study patients.Table 1. Pure inﬂuenza viral pneumonia tended to affect
young, obese patients (21.3%) presenting with a nonproduc-
tive cough. In these patients, detailed laboratory investiga-
tions revealed low white blood cell counts, and chest X-rays
showed ground-glass opacity with diffuse distribution.
Microbiological tests were performed in 196 (61.6%)
patients, and Streptococcus pneumoniae was detected as the
major agent in 67 (20.9%). Other detected pathogens included
Hemophilus inﬂuenzae (n¼10, 3.1%), methicillin-sensitive Sta-
phylococcus aureus (n¼6, 1.9%), Mycoplasma pneumoniae (n¼4,
1.3%), Moraxella catarrhalis (n¼4, 1.3%), Pseudomonas aeruginosa
(n¼4, 1.3%), Klebsiella pneumoniae (n¼2, 0.6%), Streptococcus
viridans (n¼2, 0.6%), Enterobacter cloacae (n¼1, 0.3%), and
Enterococcus faecalis (n¼1, 0.3%).
3.3. Mortality evaluation by each prediction model
The number of patients and deaths and the observed and
predicted mortality rates in each class/group according to the
PSI, CURB-65, and A-DROP are shown in Fig. 2A–C, respec-
tively. The PSI, CURB-65, and A-DROP classes/groups corre-
lated well with one another (data not shown). All routine
prediction models showed that higher mortality was related
to a higher class/grade on the Cochran–Armitage tendency
test (po0.001); however, the actual rate of mortality was
higher than that predicted from the routine CAP prediction
models [7,8,18]. The receiver operating characteristic (ROC)
curve for mortality in each prediction model (by class/score)
is shown in Fig. 4A. The highest accuracy, as evaluated by the
area under the curve, was 0.820 for A-DROP. Multiple logistic
regression analysis of PSI risk classes I versus II and I versus
III revealed no signiﬁcance between odds ratios. PSI evalua-
tion of the types of pneumonia showed that their effect on
mortality was independent (p¼0.027), especially in pure
inﬂuenza viral pneumonia (Table 2).
3.4. Severity evaluation by each prediction model
Fig. 3A–C shows the number of IPPV cases and proportion of
IPPV cases in each class/group according to the PSI, CURB-65,
and A-DROP, respectively. With regard to mortality, the use of
IPPV tended to be greater in higher classes/grades on
Cochran–Armitage tendency testing (po0.001). However, IPPV
was used even in relatively mild classes/grades. The ROC
curve for IPPV is shown in Fig. 4B. A-DROP had the highest
area under the curve, of 0.778. In multiple logistic regression
models, the need for IPPV was affected by the type of
pneumonia, particularly pure inﬂuenza viral pneumonia, in
all prediction models (Table 3). The calculations for each
prediction model for each type of pneumonia are detailed in
Fig. S1.4. Discussion
This study shows that the current routine prediction models
for CAP underestimate the true severity and mortality rates of
inﬂuenza pneumonia. Although mortality tends to be
increased in higher classes/grades, the overall mortality rates
are higher than predicted [7,8,18]. The ﬁndings suggest that
Table 1 – Patient background, symptoms, and laboratory ﬁndings in each pneumonia type.
Pure inﬂuenza viral
pneumonia n¼94
Secondary bacterial
pneumonia n¼53
Mixed viral and bacterial
pneumonia n¼127
p Value
Patient background
Age (years old, average) 47 57 58 o0.001
No underlying medical
conditions
38 (40.4) 15 (28.3) 37 (29.1) 0.154
Chronic respiratory diseases 14 (14.9) 24 (45.3) 43 (33.9) o0.001
Chronic heart diseases 5 (5.3) 3 (5.7) 20 (15.7) 0.004
Chronic renal diseases 1 (1.1) 1 (1.9) 6 (4.7) 0.073
Chronic liver diseases 2 (2.1) 1 (1.9) 4 (3.1) 0.395
Cerebrovascular disease 0 (0) 3 (5.7) 15 (11.8) o0.001
Hematological diseases 4 (4.3) 0 (0) 1 (0.8) 0.064
Diabetes mellitus 7 (7.4) 6 (11.3) 11 (8.7) 0.726
Collagen vascular diseases 2 (2.1) 0 (0) 3 (2.4) 0.529
Malignancy 3 (3.2) 1 (1.9) 1 (0.8) 0.151
Obesity 20 (21.3) 2 (3.8) 8 (6.3) 0.001
Symptom/physical examination
Productive cough 27 (29.0) 34 (64.2) 80 (63.0) o0.001
Nonproductive cough 40 (43.0) 8 (15.1) 15 (11.8) o0.001
Dyspnea 55 (59.1) 15 (28.3) 62 (48.8) 0.002
Crackles on physical examination 49 (52.7) 18 (34.0) 60 (47.2) 0.090
Laboratory test/chest X-ray ﬁndings
WBCo4000/μL 21 (22.6) 1 (1.9) 7 (5.5) o0.001
PaO2o60 Torr or SpO2o90% 43 (46.2) 17 (32.1) 52 (40.9) 0.247
Ground glass opacity 58 (69.9) 10 (19.2) 42 (33.9) o0.001
Consolidation 44 (53.0) 44 (84.6) 94 (75.8) o0.001
Extent of shadow more than 2/3
area of one lung
41 (50.0) 6 (11.8) 31 (25.4) o0.001
Data are expressed as n (%) unless otherwise indicated. Abbreviations: WBC, white blood cell; PaO2, arterial partial pressure of oxygen; and
SpO2, oxygen saturation by pulse oximetry.
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severe hypoxemia and acute respiratory distress syndrome
were more common in the 2009 inﬂuenza pandemic.
The data also suggest that inﬂuenza pneumonia is not typical
in patients with CAP. As described in previous reports, in
addition to patients with respiratory complications, those
without any underlying medical conditions were also com-
monly observed in the 2009 pandemic [19–22], and severe
inﬂuenza was found in young patients [2,3,5,15,23]. The
patient background characteristics in the present study are
similar to those reported previously.
We classiﬁed inﬂuenza pneumonia into three types
according to the deﬁnition by Louria et al. [14]. Although
judgment of pneumonia type was left to each attending
physician, pure inﬂuenza viral pneumonia seemed to be
deduced in young patients with a nonproductive cough,
ground-glass opacity on chest X-ray in the diffuse lung or
bilateral lungs, and leukocyte depression. Pure inﬂuenza viral
pneumonia is typically considered rare in interpandemic
periods [24]; however, the pattern for pure inﬂuenza viral
pneumonia is clearly distinguishable from that for typical
bacterial pneumonia, and the presence of more than a few
cases of pure inﬂuenza viral pneumonia was strongly
suggested.
In the primary measurement, higher classes/grades were
associated with increased mortality. The same tendency wasnoted even when prediction models were adapted for each
type of pneumonia in the detailed analysis. Because the
current routine prediction models are weighted by advanced
age, the severity of pneumonia might have been under-
estimated. Although similar phenomena could occur with
atypical pneumonia [25,26], atypical pathogens, especially
M. pneumoniae and Chlamydophila pneumoniae, are associated
with a generally mild clinical course and low mortality
[27,28]. On the other hand, severe pure inﬂuenza viral
pneumonia was more frequently observed during this pan-
demic period [29,30], providing a possible explanation for the
poor performance of the routine models.
Although the type of pneumonia inﬂuences the PSI and
because we failed to calculate the odds ratio for mild inﬂuenza
pneumonia, both CURB-65 and A-DROP were found to be
fair models because they were not affected by pneumonia
patterns. In addition, A-DROP showed the highest accuracy for
evaluating severity and mortality on ROC analysis.
As a secondary measurement, the trend between class/
grade and IPPV indication was similar to that of mortality. On
the other hand, in the detailed analysis that entailed adapt-
ing prediction models for each type of pneumonia, the
opposite trend was seen when adapting CURB-65 to assess
IPPV. However, the small sample size, especially in the upper
class/grade, made it difﬁcult to determine signiﬁcance. Nota-
bly, in the severity analysis, the group classiﬁed as mild
Fig. 2 – Observed and predicted mortality according to (A) pneumonia severity index (PSI), (B) CURB-65 (confusion, urea,
respiratory rate, blood pressure, and age Z65 years), and (C) A-DROP (age, dehydration, respiration, disorientation, and blood
pressure). Solid lines indicate mortality in this study, and dotted lines show predicted mortality from other reports. *po0.001
indicates a tendency of higher mortality in higher-severity classes/grades (by the Cochran–Armitage test).
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IPPV. Moreover, pure inﬂuenza viral pneumonia was found to
affect the indications for IPPV. Pneumonia prediction models
were originally used to decide on the appropriate site of care
[9,10,31]. However, the routine prediction models underesti-
mate the true severity of pneumonia and may, therefore, not
always be helpful when choosing the appropriate site.
Interestingly, type of pneumonia, especially pure inﬂu-
enza viral pneumonia, was an independent risk factor for
severity but not for mortality by the routine prediction
models. It is generally accepted that pure inﬂuenza viral
pneumonia exhibited a severe clinical course in the 2009
pandemic, but it was not associated with higher mortality in
the present study. In fact, the data show a relatively low in-
hospital mortality rate (8.6%) for pandemic inﬂuenza pneu-
monia compared with that reported in other studies (6.0–
15.2%) [29,32–34]. Other reports mentioned that one of the
factors contributing to the deaths may have been delays in
and fewer cases of oseltamivir therapy [3,35]. Our previous
report revealed a higher proportion of anti-inﬂuenza drug usein Japan, which could have contributed to the lower mortality
rate [15]. Thus, early and more widespread use of anti-
inﬂuenza viral drugs is proposed as one way to reduce
mortality [20,36].
Several limitations of this study should be noted. First, the
questionnaire was retrospective and voluntary, and the
pneumonia pattern diagnosis depended on the attending
physician's clinical judgment; thus, the true proportion of
viral/bacterial pneumonia was not necessarily reﬂected by
the data. However, many cases were reported and included
various patterns of inﬂuenza pneumonia. The data appeared
to include more than a few cases of pure inﬂuenza viral
pneumonia, which inﬂuenced pneumonia severity and indi-
cated IPPV treatment. Second, age was categorical and not
provided as detailed numerical data (in line with the gui-
dance of the Institutional Review Board), which led to
inaccurate calculations in each prediction model. However,
categorical data made the questionnaires easier to answer
and may have improved the response rate. Finally, as
described in a previous report [15], recall bias was likely a
Table 2 – Multiple logistic regression models for mortality evaluation.
p Value Odds ratio [95% CI*]
PSI
I vs. II 0.247 3.9 [0.4–38.1]
I vs. III 0.104 6.7 [0.7–67.0]
I vs. IV 0.003 23.2 [2.9–187.1]
I vs. V o0.001 105.3 [10.5–1055.1]
Types of pneumonia 0.027 –
CURB-65
Mild vs. intermediate o0.001 6.7 [2.5–18.1]
Mild vs. high 0.001 10.9 [2.8–42.0]
Types of pneumonia 0.124 –
A-DROP
Mild vs. moderate 0.012 13.8 [1.8–106.3]
Mild vs. severe o0.001 101.7 [10.1–1023.1]
Mild vs. extremely severe o0.001 104.4 [9.7–1123.8]
Types of pneumonia 0.125 –
Abbreviations: PSI, pneumonia severity index; CURB-65, confusion, urea, respiratory rate, blood pressure, and age Z65 years; and A-DROP, age,
dehydration, respiration, disorientation, and blood pressure.
n CI, Conﬁdence interval.
Fig. 3 – Proportion of invasive positive pressure ventilation (IPPV) according to (A) pneumonia severity index (PSI), (B) CURB-65,
and (C) A-DROP. Pneumonia severity was evaluated using IPPV as an indicator. *po0.001 indicates a tendency of frequent IPPV
usage in higher-severity classes/grades (by the Cochran–Armitage test).
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Fig. 4 – Discriminatory power of each prediction model by
receiver operating characteristic (AUC, area under the curve).
(a) Mortality and (b) Severity.
Table 3 – Multiple logistic regression models for severity
evaluation by IPPV usage.
p Value Odds ratio [95% CI*]
PSI
I vs. II 0.015 13.7 [1.7–112.3]
I vs. III 0.022 13.1 [1.5–117.7]
I vs. IV o0.001 72.0 [9.1–571.4]
I vs. V o0.001 116.1 [11.3–1197.6]
Types of pneumonia o0.001 –
CURB-65
Mild vs. intermediate o0.001 8.5 [3.5–20.6]
Mild vs. high 0.001 9.3 [2.5–34.3]
Types of pneumonia o0.001 –
A-DROP
Mild vs. moderate o0.001 17.5 [4.1–75.3]
Mild vs. severe 0.007 18.5 [2.3–152.0]
Mild vs. extremely severe o0.001 256.4 [30.2–2173.8]
Types of pneumonia 0.002 –
Abbreviations: IPPV, invasive positive pressure ventilation.
n CI, Conﬁdence Interval.
r e s p i r a t o r y i n v e s t i g a t i o n 5 2 ( 2 0 1 4 ) 2 8 0 – 2 8 7286factor. Nonetheless, because the study targeted almost 2500
respiratory departments at hospitals nationwide, the
responses seem reasonable and should reﬂect the trends in
pneumonia during the 2009 pandemic.5. Conclusions
Of the current pneumonia prediction models, both CURB-65
and A-DROP are fair predictors because they are not inﬂu-
enced by pneumonia patterns. However, it should be notedthat actual mortality is underestimated and that the mortal-
ity rates observed were higher than predicted. A-DROP
showed the highest accuracy, but all models underestimated
severity and the appropriate site of care for patients with
inﬂuenza pneumonia; therefore, more-appropriate models
for inﬂuenza pneumonia are required.Conﬂict of interest
This study received no ﬁnancial or material support.
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